Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Pasi A. Janne; Mengzhao Wang; D. Ross Camidge; Paul Mitchell; Jian Fang; Weiqi Nian; Chao-Hua Chiu; Jianying Zhou; Yanqiu Zhao; Wu-Chou Su; Tsung-Ying Yang; Viola Weijia Zhu; Michael Millward; Yun Fan; Wen-Tsung Huang; Ying Cheng; Liyan Jiang; Daniel Brungs; Li Zheng; James Chih-Hsin Yang

Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Pasi A. Janne, Mengzhao Wang, D. Ross Camidge, Paul Mitchell, Jian Fang, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola Weijia Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Li Zheng, James Chih-Hsin Yang

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

10 Citations (Web of Science)

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States Duration: 3 Jun 2022 → 7 Jun 2022

Cite this

Janne, P. A., Wang, M., Camidge, D. R., Mitchell, P., Fang, J., Nian, W., Chiu, C.-H., Zhou, J., Zhao, Y., Su, W.-C., Yang, T.-Y., Zhu, V. W., Millward, M., Fan, Y., Huang, W.-T., Cheng, Y., Jiang, L., Brungs, D., Zheng, L., & Yang, J. C.-H. (2022). Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures. Journal of Clinical Oncology, 40(16).

@article{6ebd0783afe1472f8fa6fb3ce6999090,

title = "Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.",

author = "Janne, {Pasi A.} and Mengzhao Wang and Camidge, {D. Ross} and Paul Mitchell and Jian Fang and Weiqi Nian and Chao-Hua Chiu and Jianying Zhou and Yanqiu Zhao and Wu-Chou Su and Tsung-Ying Yang and Zhu, {Viola Weijia} and Michael Millward and Yun Fan and Wen-Tsung Huang and Ying Cheng and Liyan Jiang and Daniel Brungs and Li Zheng and Yang, {James Chih-Hsin}",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ASCO ; Conference date: 03-06-2022 Through 07-06-2022",

}

Janne, PA, Wang, M, Camidge, DR, Mitchell, P, Fang, J, Nian, W, Chiu, C-H, Zhou, J, Zhao, Y, Su, W-C, Yang, T-Y, Zhu, VW, Millward, M, Fan, Y, Huang, W-T, Cheng, Y, Jiang, L, Brungs, D, Zheng, L & Yang, JC-H 2022, 'Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.', Journal of Clinical Oncology, vol. 40, no. 16.

TY - JOUR

T1 - Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

AU - Janne, Pasi A.

AU - Wang, Mengzhao

AU - Camidge, D. Ross

AU - Mitchell, Paul

AU - Fang, Jian

AU - Nian, Weiqi

AU - Chiu, Chao-Hua

AU - Zhou, Jianying

AU - Zhao, Yanqiu

AU - Su, Wu-Chou

AU - Yang, Tsung-Ying

AU - Zhu, Viola Weijia

AU - Millward, Michael

AU - Fan, Yun

AU - Huang, Wen-Tsung

AU - Cheng, Ying

AU - Jiang, Liyan

AU - Brungs, Daniel

AU - Zheng, Li

AU - Yang, James Chih-Hsin

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000863680302205&DestLinkType=FullRecord&DestApp=WOS

M3 - Abstract/Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 3 June 2022 through 7 June 2022

ER -

Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Other files and links

Cite this